07 August 2020 | News
ImmVira's MVR-T3011 has innovated with a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) to enhance the known oncolytic effects of oHSV-1.
Image source: PR Newswire
ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd recently announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.
ImmVira's MVR-T3011 oncolytic virus program has innovated with a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) to enhance the known oncolytic effects of oHSV-1. Through gene recombinant technologies, PD-1 antibody and interleukin-12 immune modulators are expressed within the virus. Oncolysis is achieved with additional immune response stimulation while keeping the boosted immune activity limited to the locality of MVR-T3011 to achieve a potentially favorable safety profile.
The MVR-T3011 intratumoral program aims to target most solid malignant tumors with both remission rate improvement and safety improvement over immune modulator monotherapies. As part of the agreement, Shanghai Pharma will receive an exclusive license and gain access to ImmVira's MVR-T3011 virus for clinical development, manufacturing and commercialization within certain fields of use in mainland China, Hong Kong, Macau and Taiwan (the Greater China region). ImmVira and Shanghai Pharma will collaborate on clinical trials in China with exclusive commercial rights for intratumoral therapies developed under the agreement assigned to Shanghai Pharma for the Greater China region.
Under the terms of the agreement, ImmVira will receive from Shanghai Pharma an upfront payment and contingent milestone payments that would in the aggregate amount to RMB1.15 billion, as well as royalty payments of up to 12% of net revenues should Shanghai Pharma successfully commercialize a therapy from the collaboration.